# Tesamorelin: Approved, But For One Thing Only > Tesamorelin: Research Overview — mypeptidesrx — A skeptic's literature summary of tesamorelin, the GHRH analogue approved in 2010 for one indication only — mechanism, the trial evidence behind that approval, and where the popular off-label use cases stand. **03 / RESEARCH PEPTIDE FUNDAMENTALS — LEAD COMPOUND** A GHRH analogue with a single FDA indication from 2010 — everything else it is used for today is off-label, and this page keeps that line visible rather than blurring it. ## The short version Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — it doesn't supply growth hormone directly, it prompts the pituitary gland to release more of its own, in the body's natural pulsatile pattern. It was FDA-approved in 2010 for exactly one thing: reducing excess visceral (abdominal) fat in people with HIV-associated lipodystrophy, a specific fat-redistribution condition linked to antiretroviral therapy. That is the whole approved indication. Every other use discussed for tesamorelin — general visceral-fat reduction outside HIV, anti-aging, cognitive enhancement, athletic performance — is off-label and, for most of those uses, not backed by the kind of large randomized trial that supports the HIV indication. It is also the peptide on this desk with the least community-reported data available to summarize: unlike semaglutide and tirzepatide, there is no substantial anecdotal-effects literature compiled for tesamorelin in this digest, which this page states plainly rather than filling in with speculation. ## What it is Tesamorelin is a 44-amino-acid synthetic analogue of human GHRH — specifically GHRH(1-44)-NH2 — with a trans-3-hexenoic acid group attached at the N-terminus. That modification is the whole trick: it blocks the enzyme (DPP-IV) that would otherwise rapidly cleave the peptide, extending its usable window in the bloodstream relative to native GHRH. It is supplied clinically as the acetate salt, given by subcutaneous injection. Unlike semaglutide and tirzepatide, tesamorelin does not act on the GLP-1/GIP incretin system at all — it sits one step upstream, on the growth-hormone axis, a structurally and clinically distinct branch of endocrinology. That distinction is why it belongs on this desk despite having almost nothing in common mechanistically with the other two: all three answer the same organizing question — how does a research peptide actually earn a prescription-drug approval — from three different directions. ## How it works Tesamorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, activating a Gs-protein/adenylyl-cyclase/cAMP signaling cascade that stimulates the synthesis and pulsatile release of the body's own growth hormone (GH). That GH then drives the liver to produce insulin-like growth factor-1 (IGF-1), and together GH and IGF-1 promote lipolysis with a documented preference for visceral fat over other fat depots. The 'stimulates your own supply' framing matters clinically, not just semantically. Because tesamorelin amplifies an existing pulsatile rhythm rather than supplying a flat, exogenous dose of hormone, its metabolic side-effect profile differs from giving recombinant growth hormone directly — a small controlled study in healthy men found it raised overnight GH and IGF-1 significantly without producing a measurable effect on fasting glucose or insulin-stimulated glucose uptake, which is a reassuring but genuinely small (n=13), short (2-week) piece of evidence rather than a settled finding [13]. ## What the research shows *Most recent evidence — 2026 meta-analysis.* Pooling five randomized controlled trials in HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 cm2 (95% CI -38.37 to -17.06, P<0.001), reduced trunk fat by 1.18 kg and hepatic fat fraction by 4.28 percentage points, and increased lean body mass by 1.42 kg, all P<0.001, with no serious adverse events reported across the pooled trials [10]. Five trials is a real evidence base for this indication, but it is worth naming plainly: five trials in one specific population is a much thinner base than the tens of thousands of participant-years behind semaglutide or tirzepatide. *Pivotal approval trial.* The 26-week Phase 3 trial behind the 2010 approval, in 412 HIV patients with abdominal fat accumulation, found tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo increased it by 5.0%; triglycerides fell by 50 mg/dL versus a 9 mg/dL increase on placebo, and IGF-1 rose 81.0% [15]. *Durability and reversibility.* Over the full 52-week program (n=273 tesamorelin, n=137 placebo), the visceral-fat reduction held at roughly -18% (P<0.001 vs baseline) — but fat reaccumulated once the drug was stopped, and glucose-parameter changes over the full year were not clinically significant [14]. That reaccumulation finding matters: it frames tesamorelin, like semaglutide and tirzepatide, as a treatment that requires continued use to sustain its effect rather than a one-time correction. *Liver-injury profile.* The NIH LiverTox monograph assigns tesamorelin a likelihood score of E — unlikely to cause clinically apparent liver injury — noting no attributable liver-injury cases and no de novo enzyme elevations across the trial record as of its review [11]. *Where the evidence stops.* A 2026 structured narrative review of injectable peptides in sports medicine groups tesamorelin with other growth-hormone-axis secretagogues (alongside CJC-1295 and ipamorelin) as investigational outside its approved indication, flagging uncertain safety profiles, product-quality concerns in the non-pharmaceutical supply chain, and near-universal antidoping restrictions across that category [16]. That review is describing the off-label and research-grade use case specifically — not the approved HIV indication, where the evidence above is considerably firmer. ## Reported effects, cautions & safety *A note on what's missing here.* Unlike the semaglutide and tirzepatide pages, this digest has no compiled community-reported effects data for tesamorelin — no forum-derived benefit or side-effect list to summarize. Rather than inventing one, this section states that gap directly and sticks to what the cited literature actually documents. *What the trial and review literature documents.* Tesamorelin's approval is bounded tightly: it covers HIV-associated lipodystrophy specifically, and results in that population may not generalize to other uses without dedicated trials, which for most off-label applications do not yet exist [11][15]. Because tesamorelin raises IGF-1 — a growth factor — active malignancy is a labeled contraindication; trials through 52 weeks showed no excess malignancy signal, but that window is short relative to a lifetime, and the review literature does not claim long-term oncologic safety has been established either way [14]. Glucose effects appear modest in the trial record: a 2011 study in healthy men found no significant change in fasting glucose or insulin-stimulated glucose uptake over two weeks [13], and the full 52-week program likewise found glucose changes that were not clinically significant [14] — but people with pre-existing dysglycemia were not the focus of those trials, and monitoring remains the standard recommendation. Tesamorelin is also on the WADA Prohibited List as a GHRH analogue (category S2), in- and out-of-competition — a compliance fact, not a safety finding, but relevant to anyone researching it in an athletic context. And the broader class it belongs to — growth-hormone-axis secretagogues sold outside the approved product — carries documented product-quality concerns that the approved, prescribed formulation does not share [16]. ## Where it fits in Research Peptide Fundamentals Tesamorelin is the lead compound on this desk precisely because it complicates the tidy version of the 'crossed into prescription medicine' story. It genuinely holds an FDA approval, and the evidence behind that approval — five pooled RCTs as of 2026, a 412-person pivotal trial, a full 52-week safety program — is real [10][14][15]. But the approval is narrow, the population studied is specific, and almost every popular use of tesamorelin sits outside what was actually tested. [Semaglutide](/semaglutide) and [tirzepatide](/tirzepatide) show what a broad, deeply replicated approval looks like; tesamorelin shows what a narrow one looks like from the inside. The [comparison page](/compare) puts all three side by side on exactly this dimension. ![Tesamorelin research illustration](/images/tesamorelin.webp) --- An independent research summary that reports evidence quality honestly, including where it's thin — not a clinic, not a pharmacy, not medical advice.